293 related articles for article (PubMed ID: 14578481)
21. A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: a potential therapy for type 2 diabetes.
Tsutsumi M; Claus TH; Liang Y; Li Y; Yang L; Zhu J; Dela Cruz F; Peng X; Chen H; Yung SL; Hamren S; Livingston JN; Pan CQ
Diabetes; 2002 May; 51(5):1453-60. PubMed ID: 11978642
[TBL] [Abstract][Full Text] [Related]
22. Cytosolic Ca2+ responses to sub-picomolar and nanomolar PACAP in pancreatic beta-cells are mediated by VPAC2 and PAC1 receptors.
Yamada H; Watanabe M; Yada T
Regul Pept; 2004 Dec; 123(1-3):147-53. PubMed ID: 15518905
[TBL] [Abstract][Full Text] [Related]
23. Development-related splicing regulates pituitary adenylate cyclase-activating polypeptide (PACAP) receptors in the retina.
Lakk M; Szabó B; Völgyi B; Gábriel R; Dénes V
Invest Ophthalmol Vis Sci; 2012 Nov; 53(12):7825-32. PubMed ID: 23099490
[TBL] [Abstract][Full Text] [Related]
24. VIP/PACAP receptors in cerebral arteries of rat: characterization, localization and relation to intracellular calcium.
Erdling A; Sheykhzade M; Maddahi A; Bari F; Edvinsson L
Neuropeptides; 2013 Apr; 47(2):85-92. PubMed ID: 23375386
[TBL] [Abstract][Full Text] [Related]
25. Distribution of vasoactive intestinal peptide, pituitary adenylate cyclase-activating peptide, nitric oxide synthase, and their receptors in human and rat sphenopalatine ganglion.
Csati A; Tajti J; Kuris A; Tuka B; Edvinsson L; Warfvinge K
Neuroscience; 2012 Jan; 202():158-68. PubMed ID: 22108610
[TBL] [Abstract][Full Text] [Related]
26. (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.
Moody TW; Jensen RT; Fridkin M; Gozes I
J Mol Neurosci; 2002; 18(1-2):29-35. PubMed ID: 11931347
[TBL] [Abstract][Full Text] [Related]
27. Backup Mechanisms Maintain PACAP/VIP-Induced Arterial Relaxations in Pituitary Adenylate Cyclase-Activating Polypeptide-Deficient Mice.
Ivic I; Fulop BD; Juhasz T; Reglodi D; Toth G; Hashimoto H; Tamas A; Koller A
J Vasc Res; 2017; 54(3):180-192. PubMed ID: 28490016
[TBL] [Abstract][Full Text] [Related]
28. Vasoactive intestinal peptide (VIP) stimulates cortisol secretion from the H295 human adrenocortical tumour cell line via VPAC1 receptors.
Nicol MR; Cobb VJ; Williams BC; Morley SD; Walker SW; Mason JI
J Mol Endocrinol; 2004 Jun; 32(3):869-77. PubMed ID: 15171718
[TBL] [Abstract][Full Text] [Related]
29. Analysis of the role of the PAC1 receptor in neutrophil recruitment, acute-phase response, and nitric oxide production in septic shock.
Martínez C; Juarranz Y; Abad C; Arranz A; Miguel BG; Rosignoli F; Leceta J; Gomariz RP
J Leukoc Biol; 2005 May; 77(5):729-38. PubMed ID: 15661828
[TBL] [Abstract][Full Text] [Related]
30. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells.
Nagakawa O; Junicho A; Akashi T; Koizumi K; Matsuda T; Fuse H; Saiki I
Oncol Rep; 2005 Jun; 13(6):1217-21. PubMed ID: 15870945
[TBL] [Abstract][Full Text] [Related]
31. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation.
Delgado M; Munoz-Elias EJ; Gomariz RP; Ganea D
J Immunol; 1999 Apr; 162(8):4685-96. PubMed ID: 10202009
[TBL] [Abstract][Full Text] [Related]
32. All D-VIP mitigates vasodilation elicited by L-VIP, micellar L-VIP and micellar PACAP1-38, but not PACAP1-38, in vivo.
Rubinstein I; Ashok B; Tsueshita T; Onyüksel H
Peptides; 2005 Mar; 26(3):509-15. PubMed ID: 15652658
[TBL] [Abstract][Full Text] [Related]
33. Drug Repositioning For Allosteric Modulation of VIP and PACAP Receptors.
Langer I; Latek D
Front Endocrinol (Lausanne); 2021; 12():711906. PubMed ID: 34867774
[TBL] [Abstract][Full Text] [Related]
34. cAMP activation by PACAP/VIP stimulates IL-6 release and inhibits osteoblastic differentiation through VPAC2 receptor in osteoblastic MC3T3 cells.
Nagata A; Tanaka T; Minezawa A; Poyurovsky M; Mayama T; Suzuki S; Hashimoto N; Yoshida T; Suyama K; Miyata A; Hosokawa H; Nakayama T; Tatsuno I
J Cell Physiol; 2009 Oct; 221(1):75-83. PubMed ID: 19496170
[TBL] [Abstract][Full Text] [Related]
35. Hexanoylation of a VPAC2 receptor-preferring ligand markedly increased its selectivity and potency.
Langer I; Gregoire F; Nachtergael I; De Neef P; Vertongen P; Robberecht P
Peptides; 2004 Feb; 25(2):275-8. PubMed ID: 15063009
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of vasoactive intestinal peptide-elicited coronary vasodilation in the isolated perfused rat heart.
Sawmiller DR; Ashtari M; Urueta H; Leschinsky M; Henning RJ
Neuropeptides; 2006 Oct; 40(5):349-55. PubMed ID: 17030371
[TBL] [Abstract][Full Text] [Related]
37. Ageing and the diurnal expression of mRNAs for vasoactive intestinal peptide and for the VPAC2 and PAC1 receptors in the suprachiasmatic nucleus of male rats.
Kalló I; Kalamatianos T; Piggins HD; Coen CW
J Neuroendocrinol; 2004 Sep; 16(9):758-66. PubMed ID: 15344914
[TBL] [Abstract][Full Text] [Related]
38. Cardioprotective role of the VIP signaling system.
Dvoráková MC
Drug News Perspect; 2005; 18(6):387-91. PubMed ID: 16247516
[TBL] [Abstract][Full Text] [Related]
39. Localization of the neuropeptides pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal peptide, and their receptors in the basal brain blood vessels and trigeminal ganglion of the mouse CNS; an immunohistochemical study.
Lund AM; Hannibal J
Front Neuroanat; 2022; 16():991403. PubMed ID: 36387999
[TBL] [Abstract][Full Text] [Related]
40. Early changes in pituitary adenylate cyclase-activating peptide, vasoactive intestinal peptide and related receptors expression in retina of streptozotocin-induced diabetic rats.
Giunta S; Castorina A; Bucolo C; Magro G; Drago F; D'Agata V
Peptides; 2012 Sep; 37(1):32-9. PubMed ID: 22721946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]